VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Cullinan Therapeutics, Inc. (CGEM) Total Return Calculator with Dividends Reinvested

Cullinan Therapeutics, Inc.

Popular:

The total return for Cullinan Therapeutics, Inc. (CGEM) stock is +91.17% over the past 12 months. So far it's up 45.45% this year. The 5-year total return is -50.70%, meaning $10,000 invested in CGEM stock 5 years ago would be worth $4,930 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CGEM 1 year ago, it would be worth $18,945 today — you'd have gained $8,945.

With Dividends Reinvested$18,945+89.45%

Price Only (No DRIP)$18,945+89.45%

Period2025-05-08 → 2026-05-07

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CGEM

1Y$19,117+$9,117 (+91.2%)91.2% CAGR

3Y$15,478+$5,478 (+54.8%)15.7% CAGR

5Y$4,930-$5,070 (-50.7%)-13.2% CAGR

10Y$4,921-$5,079 (-50.8%)-6.8% CAGR

15Y$4,921-$5,079 (-50.8%)-4.6% CAGR

20Y$4,921-$5,079 (-50.8%)-3.5% CAGR

30Y$4,921-$5,079 (-50.8%)-2.3% CAGR

Cullinan Therapeutics, Inc. did not pay dividends during this period. Total return = price return.

Loading CGEM total return...

As of 2026-05-08

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+45.45%	—	+45.45%	—	$14,545
1Y	+91.17%	91.17%	+91.17%	—	$19,117
3Y	+54.78%	15.68%	+54.78%	—	$15,478
5Y	-50.70%	-13.19%	-50.70%	—	$4,930
10Y	-50.79%	-6.84%	-50.79%	—	$4,921
15Y	-50.79%	-4.62%	-50.79%	—	$4,921
20Y	-50.79%	-3.48%	-50.79%	—	$4,921
30Y	-50.79%	-2.34%	-50.79%	—	$4,921

Risk & Highlights

Best Year+15.01%2024

Worst Year-48.41%2021

Max Drawdown-36.67%2025-06-06 → 2025-10-02 · Recovered 2025-11-21

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	+53.16%	+53.16%	—	+0.41%	+52.7pp
2025	-16.46%	-16.46%	—	+16.64%	-33.1pp
2024	+15.01%	+15.01%	—	+24.00%	-9.0pp
2023	-4.59%	-4.59%	—	+24.81%	-29.4pp
2022	-36.02%	-36.02%	—	-19.95%	-16.1pp

CGEM outperformed the S&P 500 by 60.80pp over the past year (+91.17% vs +30.37%).

Loading summary...

CGEM Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CGEMCullinan Therapeutics, Inc.	$905M	-0.9%	+45.5%	+91.2%	—	+54.8%	-50.7%	-50.8%
IMVTImmunovant, Inc.	$5.5B	+10.6%	+5.1%	+96.1%	—	+40.9%	+62.4%	+173.6%
KYMRKymera Therapeutics, Inc.	$6.9B	-0.6%	+16.3%	+190.7%	—	+205.1%	+92.1%	+154.4%
RCUSArcus Biosciences, Inc.	$2.5B	+12.3%	+6.5%	+209.6%	—	+24.9%	-18.6%	+45.9%
PRCTPROCEPT BioRobotics Corporation	$1.4B	+9.7%	-17.3%	-52.1%	—	-7.8%	-39.3%	-39.3%
TPSTTempest Therapeutics, Inc.	$55M	+26.3%	-33.2%	-69.3%	—	-92.6%	-88.0%	-99.9%
AGENAgenus Inc.	$132M	-7.6%	+16.1%	+27.1%	—	-88.2%	-93.9%	-94.3%
NKTRNektar Therapeutics	$1.7B	+9.4%	+92.0%	+818.2%	—	+621.8%	-72.3%	-59.1%
ALNYAlnylam Pharmaceuticals, Inc.	$39.5B	-7.4%	-26.1%	+7.0%	—	+40.9%	+125.4%	+411.9%
FATEFate Therapeutics, Inc.	$280M	+111.3%	+145.5%	+143.0%	—	-55.4%	-96.8%	+40.5%
BEAMBeam Therapeutics Inc.	$3.2B	+28.5%	+16.0%	+93.9%	—	-5.6%	-55.6%	+67.8%

Compare:CGEM vs IMVT CGEM vs KYMR CGEM vs RCUS CGEM vs IMVT vs KYMR

About CGEM Dividend Returns

Cullinan Therapeutics, Inc. (CGEM) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CGEM over the past year?

Cullinan Therapeutics, Inc. (CGEM) delivered a return of 91.17% over the past year. Since CGEM does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CGEM be worth today?

A $10,000 investment in Cullinan Therapeutics, Inc. one year ago would be worth $19,117 today, representing a gain of $9,117.

Q3Does CGEM pay dividends?

Cullinan Therapeutics, Inc. (CGEM) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CGEM, the total return equals the price-only return.

Q4Did CGEM beat the S&P 500?

Yes, Cullinan Therapeutics, Inc. (CGEM) outperformed the S&P 500 by 60.80 percentage points over the past year. CGEM delivered a total return of 91.17%, compared to the S&P 500's 30.37%. This 60.80pp alpha means investors in CGEM earned more than a passive S&P 500 index fund.

Q5What is CGEM's worst drawdown?

Cullinan Therapeutics, Inc. (CGEM) experienced a maximum drawdown of -36.67% over the past year, declining from its peak on 2025-06-06 to its trough on 2025-10-02. The stock recovered to its prior peak by 2025-11-21. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CGEM's long-term total return over 10, 20, or 30 years?

Here are Cullinan Therapeutics, Inc. (CGEM)'s long-term returns with dividends reinvested. Over 10 years, the total return is -50.8% (-6.8% CAGR) — $10,000 would have grown to $4,921. Over 20 years: -50.8% total return (-3.5% CAGR) — $10,000 → $4,921. Over 30 years: -50.8% total return (-2.3% CAGR) — $10,000 → $4,921. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CGEM's best and worst year?

Cullinan Therapeutics, Inc.'s best calendar year was 2024 with a total return of 15.0%. Its worst year was 2021 with a total return of -48.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 63.4 percentage points.